ATE249215T1 - Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose - Google Patents

Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose

Info

Publication number
ATE249215T1
ATE249215T1 AT93901204T AT93901204T ATE249215T1 AT E249215 T1 ATE249215 T1 AT E249215T1 AT 93901204 T AT93901204 T AT 93901204T AT 93901204 T AT93901204 T AT 93901204T AT E249215 T1 ATE249215 T1 AT E249215T1
Authority
AT
Austria
Prior art keywords
app
amyloidosis
modulators
medication
produce
Prior art date
Application number
AT93901204T
Other languages
English (en)
Inventor
Samuel E Gandy
Gregg L Caporaso
Paul Greengard
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Application granted granted Critical
Publication of ATE249215T1 publication Critical patent/ATE249215T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Basic Packing Technique (AREA)
  • Peptides Or Proteins (AREA)
  • Percussion Or Vibration Massage (AREA)
AT93901204T 1991-12-17 1992-12-17 Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose ATE249215T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/809,174 US5242932A (en) 1991-12-17 1991-12-17 Treatment of amyloidosis associated with alzheimer disease
PCT/US1992/010961 WO1993011762A1 (en) 1991-12-17 1992-12-17 Use of app modulators for the manufacture of a medicament for the treatment of amyloidosis

Publications (1)

Publication Number Publication Date
ATE249215T1 true ATE249215T1 (de) 2003-09-15

Family

ID=25200707

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93901204T ATE249215T1 (de) 1991-12-17 1992-12-17 Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose

Country Status (8)

Country Link
US (2) US5242932A (de)
EP (1) EP0617619B1 (de)
JP (1) JPH07501554A (de)
AT (1) ATE249215T1 (de)
AU (1) AU678159B2 (de)
CA (1) CA2126083C (de)
DE (1) DE69233195T2 (de)
WO (1) WO1993011762A1 (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
TW327194B (en) * 1992-05-01 1998-02-21 American Cyanamid Co Novel amyloid precursor proteins and methods of using same
WO1994009370A1 (en) * 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Release of alzheimer amyloid precursor stimulated by activation of muscarinic acetylcholine receptors
AU6233394A (en) * 1993-01-27 1994-08-15 Ariad Pharmaceuticals, Inc. Lactones and their pharmaceutical applications
US20040208875A1 (en) * 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
US5972328A (en) * 1993-03-29 1999-10-26 Queen's University At Kingston Method for treating amyloidosis
EP0691844A1 (de) * 1993-03-29 1996-01-17 Queen's University At Kingston Verfahren zur behandlung von amyloidosis
US5840294A (en) * 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
US5643562A (en) * 1993-03-29 1997-07-01 Queen's University Of Kingston Method for treating amyloidosis
CN1136327A (zh) * 1993-09-28 1996-11-20 综合医院公司 用反义寡核苷酸调节神经生长并使β/A4淀粉样肽诱导的形态逆转
WO1995019178A1 (en) * 1994-01-13 1995-07-20 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
JPH09511492A (ja) * 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US5523295A (en) * 1994-07-06 1996-06-04 Brandeis University Method for treating and preventing alzheimer's disease
US6365414B1 (en) * 1994-08-26 2002-04-02 The General Hospital Corporation Vitro system for determining formation of Aβ amyloid
DE69515321T2 (de) * 1994-09-20 2000-08-24 The Regents Of The University Of California, Oakland Brefeldin a und analoge zur verbesserung synaptischer übertragungen
US5972634A (en) 1994-10-19 1999-10-26 The General Hospital Corporation Diagnostic assay for Alzheimer's disease: assessment of Aβ abnormalities
GB9421472D0 (en) * 1994-10-25 1994-12-07 Smithkline Beecham Plc Novel methods
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5863902A (en) * 1995-01-06 1999-01-26 Sibia Neurosciences, Inc. Methods of treating neurodegenerative disorders using protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5783434A (en) * 1995-06-06 1998-07-21 Tung; Jay S. Cathepsin and methods and compositions for inhibition thereof
CA2221684A1 (en) * 1995-06-06 1996-12-12 Athena Neurosciences, Inc. Novel cathepsin and methods and compositions for inhibition thereof
US5849711A (en) * 1995-06-06 1998-12-15 Athena Neurosciences, Inc. Cathepsin and methods and compositions for inhibition thereof
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
CA2279651A1 (en) 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6184248B1 (en) 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043256A (en) * 1996-09-16 2000-03-28 Grassetti; Davide R. Antimutagenic agents
US6043283A (en) * 1996-09-20 2000-03-28 Baylor College Of Medicine Tyramine compounds and their neuronal effects
US6071493A (en) 1996-09-20 2000-06-06 Baylor College Of Medicine Method of screening for an agent that inhibits mononuclear phagocyte-plaque component complex formation
BR9807980A (pt) * 1997-02-05 2000-03-28 Allelix Pharm Eco L P Uso de um composto e composto para tratar um mamìfero com disfunção cognitiva
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
KR20010020611A (ko) * 1997-07-01 2001-03-15 아테로제닉스, 인코포레이티드 항산화제에 의한 과증식질병 치료의 향상
DK1014996T3 (da) * 1997-08-28 2003-09-29 Univ Washington Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser
US20020022657A1 (en) * 1998-02-11 2002-02-21 Francine Gervais Methods for modulating neuronal cell death
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US7795246B2 (en) * 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6767898B2 (en) * 1998-08-28 2004-07-27 University Of Washington Methods for using specific saccharides for treating alzheimer's disease and other amyloidoses
CA2344316A1 (en) * 1998-09-16 2000-03-23 Saira Sayed Singh Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
CA2369997C (en) * 1999-04-28 2009-11-17 Queen's University At Kingston Compositions and methods for treating amyloidosis
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
WO2002028387A1 (en) 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
ES2305234T3 (es) 2001-02-27 2008-11-01 Blanchette Rockefeller Neurosciences Institute Diagnostico de la enfermedad de alzheimer basado en la fosforilacion de una proteina quinosa activada por mitogeno.
US6664520B2 (en) * 2001-05-21 2003-12-16 Thermal Solutions, Inc. Thermal seat and thermal device dispensing and vending system employing RFID-based induction heating devices
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
US20090030055A1 (en) * 2002-07-02 2009-01-29 Thomas Nelson PKC activation as a means for enhancing sAPPALPHA secretion and improving cognition using bryostatin type compounds
WO2004028468A2 (en) * 2002-09-27 2004-04-08 Children's Medical Center Corporation Methods and compositions for treatment of neurological disorder
US7595308B2 (en) * 2002-11-18 2009-09-29 Grenpharma Llc Compositions for treating and/or preventing diseases characterized by the presence of metal ions
US6916627B2 (en) * 2002-11-27 2005-07-12 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7108992B2 (en) * 2002-11-27 2006-09-19 St. Jude Children's Research Hospital ATM kinase compositions and methods
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2005016196A1 (en) * 2003-08-04 2005-02-24 Trustees Of Dartmouth College Compositions and methods for destabilizing lysosomes to increase oncogenic or aberrant protein degradation
WO2006047477A1 (en) * 2004-10-22 2006-05-04 Grenpharama Llc Compositions for treating and/or preventing diseases characterized by the presence of the metal ions
AU2005310986A1 (en) * 2004-11-12 2006-06-08 Bellus Health (International) Limited Methods and fluorinated compositions for treating amyloid-related diseases
WO2006054979A1 (en) * 2004-11-15 2006-05-26 Blanchette Rockefeller Neurosciences Institute Abnormalities of phosphatase 2a (pp2a) for diagnosis and treatment of alzheimer’s disease
AU2005310979A1 (en) * 2004-11-16 2006-06-08 Bellus Health (International) Limited Compounds for the treatment of CNS and amyloid associated diseases
EP1836161B1 (de) * 2004-12-22 2016-07-20 BHI Limited Partnership Verfahren und zusammensetzungen zur behandlung von amyloidassoziierten krankheiten
TW200716088A (en) * 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
US20070054890A1 (en) * 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
US20090029873A1 (en) * 2005-10-11 2009-01-29 Blanchette Rockefeller Neurosciences Institute Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb)
ATE481094T1 (de) * 2005-12-22 2010-10-15 Kiacta Sarl Behandlung von diabetischer nephropathie
CN1991364A (zh) 2005-12-26 2007-07-04 中国科学院上海生命科学研究院 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂
SI2089417T1 (sl) 2006-10-12 2015-04-30 Bhi Limited Partnership Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline
CA2673022A1 (en) * 2006-12-22 2008-07-03 Bellus Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
WO2009067221A2 (en) * 2007-11-20 2009-05-28 Cephalon, Inc. Microemulsion containing indolocarbazole compound and dosage forms containing the same
EP3403650A3 (de) 2008-07-28 2019-02-13 Blanchette Rockefeller Neurosciences, Institute Pkc-aktivierende verbindungen zur behandlung von neurodegenerativen erkrankungen
EP2669386A1 (de) * 2008-07-28 2013-12-04 Blanchette Rockefeller Neurosciences Institute Stimulierte ausgelöste genomische Profilmarker von Morbus Alzheimer
CN102395366A (zh) * 2009-04-14 2012-03-28 金·尼古拉斯·格林 降低前ADAM10分泌酶和/或β分泌酶水平的方法
CN102573839A (zh) * 2009-05-11 2012-07-11 加利福尼亚大学董事会 降低泛素化蛋白水平的方法
CA2776501C (en) * 2009-10-02 2022-04-19 Blanchette Rockefeller Neurosciences Institute Fibroblast growth patterns for diagnosis of alzheimer's disease
EP2483695A2 (de) * 2009-10-02 2012-08-08 Blanchette Rockefeller Neurosciences, Institute Unnormale änderungen der verarbeitung von pkc-isozymen in morbus-alzheimer-peripherzellen
US8680095B2 (en) * 2009-12-16 2014-03-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US9309307B2 (en) * 2011-01-07 2016-04-12 Seiko Epson Corporation Antibody against amyloid precursor protein signal peptide
WO2013071281A1 (en) 2011-11-13 2013-05-16 Blanchette Rockefeller Neurosciences Institute Esters of dcpla and methods of treatment using the same
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806537A (en) * 1987-04-16 1989-02-21 City Of Hope Use of amodiaquin and related compounds in treatment of nervous system degeneration
CA2011086A1 (en) * 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
US4916135A (en) * 1989-05-08 1990-04-10 Hoechst Roussel Pharmaceuticals Inc. N-heteroaryl-4-quinolinamines
US5213962A (en) * 1990-04-24 1993-05-25 The Regents Of The University Of California Purification, detection and methods of use of protease Nexin-2
JPH0725786A (ja) * 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
US5093333A (en) * 1991-04-29 1992-03-03 American Home Products Corporation N-substituted-2-aminoquinolines useful for treating hypofunction of the cholinergic system

Also Published As

Publication number Publication date
WO1993011762A1 (en) 1993-06-24
AU4035793A (en) 1993-07-19
EP0617619A1 (de) 1994-10-05
DE69233195T2 (de) 2004-04-01
CA2126083C (en) 2004-06-15
AU678159B2 (en) 1997-05-22
JPH07501554A (ja) 1995-02-16
US5242932A (en) 1993-09-07
DE69233195D1 (de) 2003-10-16
US5348963A (en) 1994-09-20
CA2126083A1 (en) 1993-06-24
EP0617619B1 (de) 2003-09-10

Similar Documents

Publication Publication Date Title
DE69233195D1 (de) Verwendung von app-modulatoren zur herstellung eines medikamentes zur behandlung der amyloidose
ATE180408T1 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
NO308794B1 (no) Farmakologisk aktive pyridin-derivater, preparater inneholdende forbindelsene samt forbindelsenes anvendelse
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
FI893433A0 (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
ATE217754T1 (de) Verwendung von aerogelen in der landwirtschaft
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE69939864D1 (de) Ppar-gamma modulatoren
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
DE69100364D1 (de) Verwendung von N-Myristoyl-(S)-Phenylalanin zur Herstellung eines Medikaments zur Behandlung von Krankheiten mittels Hemmung der Myristoylierung.
KR900004256A (ko) 살균제
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
ATE237633T1 (de) Analogen des keratinozytenwachstumfaktors
ATE135577T1 (de) Verwendung von buspiron zur herstellung eines pharmazeutischen präparats zur behandlung der alkoholsucht
ATE175112T1 (de) Verwendung von taurin zur herstellung eines medikaments zur stimulierung der myeloperoxidaseaktivität
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ES483661A1 (es) Procedimiento para la obtencion de derivados de 1,4-dihidro-piridina sila-sustituidos
DE3688528D1 (de) Optische analoge datenverarbeitungsanordnungen zur behandlung von bipolaren und komplexen daten.
ATE11217T1 (de) Antibiotische substanzen, verfahren zu deren herstellung und deren zusammensetzungen; stamm von staphylococcus epidermidis, welcher diese antibiotische substanz produziert und deren zusammensetzungen.
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE24282T1 (de) Verfahren zur herstellung von pharmazeutischen und kosmetischen dispersionen.
ATE23112T1 (de) Verwendung von 1-(p-isopropoxyethoxymethylphenoxy)-3-isopropylamino-propan-2-ol zur herstellung eines arzneimittels zur senkung des augeninnendrucks.
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE69606777D1 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties